Cancer treatment using SABR

01483 571122

1. In June of this year your hospital was selected to take part in NHS England’s new Commissioning through Evaluation programme to assess the value of treating certain cancer patients with Stereotactic Ablative Radiotherapy (SABR). Which platform are you using to deliver SABR? Varian Truebeam

1a How many patients have you treated with SABR under this programme? Zero

1b. Which indications have you treated? N/A

1.c. How many patients do you plan to treat before April 2016? 1-2 per month once the RTQA approval to begin treatment is received

1d. Does the tariff you receive for this programme adequately cover the costs of delivering the treatment? It would do so

2. Does your hospital deliver Stereotactic Radiosurgery (SRS) for benign or malignant tumours of the brain? No2a. Which platform do you use to deliver this treatment? N/AGamma Knife, CyberKnife, Varian Edge, Other: Please specify2b. How many patients have you treated since April 2015? N/A2c. Which indications have you treated? N/A2d. How many patients do you plan to treat by April 2016? N/A2e. Does the tariff you receive adequately cover the costs of delivering the treatment? N/A